Amarin Corp Plc (AMRN)

[Biobillionair]

The date is approaching where NCE granted 7-26-2012 and NME 12-20-2013 are equal at short term asset valuation. At this point overhang is gone.

The "you can't touch this patent" is 8298554, it's OB'd and solid. It also happens to be the reason the USP change the chemical name of Icosapent Ethyl to "Icosapent Ethyl Capsule".

No EPA generic can compete without the product spoiling. No product containing massive amounts of preservatives can achieve the 1000 mg of EPA per cap. No capsule filled with less than 1000 mg can achieve EPA blood levels of 347 mcg/ml to be considered equivalent. No one could get API cheaper than Amarin.

8298554

http://www.google.com/patents/US8298554?dq=8298554&hl=en&sa=X&ei=j3iXUZWTGI-HqwHGxoHwDg&ved=0CDMQ6AEwAA

Anchor approval sinks Lovaza from the reimbursement angle, unless you want to pay out of pocket Lovaza is done 12-20-2013.